Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Paul De La O

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Cell Cycle (Georgetown, Tex.)|May 15, 2009
Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signalingJean-Paul De La O, L Charles Murtaugh
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2015
Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived XenograftsMagdalena Bieniasz, Parvathi Radhakrishnan, Najme Faham, et al.
Disease Models & Mechanisms|January 24, 2012
β-catenin is selectively required for the expansion and regeneration of mature pancreatic acinar cells in miceMatthew D Keefe, Hui Wang, Jean-Paul De La O, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 26, 2008
Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasiaJean-Paul De La O, Lyska L Emerson, Jessica L Goodman, et al.
The Oncologist|June 17, 2024
Associations with other cancer-related biomarkers might contribute to poor outcomes in RAS-altered, younger patients with colorectal cancerMadappa N Kundranda, Ariane C Kemkes, Mark C Evans, et al.
Breast Cancer Research : BCR|January 20, 2026
Characterization of ESR1 alterations in patients with breast and gynecologic cancersGargi D Basu, Paige E Innis, Angela K Deem, et al.
Oncotarget|July 25, 2025
Comprehensive genomic profiling of over 10,000 advanced solid tumorsJean-Paul De La O, Jess R Hoag, Angela K Deem, et al.
Journal of Medical Economics|March 31, 2026
Costs and benefits of whole-exome, whole-transcriptome sequencing versus 50-gene panels for genomic profiling in solid tumorsJesse D Ortendahl, Gebra Cuyun Carter, Eliza M Zantema, et al.
Elife|July 8, 2015
The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinomaNathan M Krah, Jean-Paul De La O, Galvin H Swift, et al.
British Journal of Cancer|December 1, 2020
RON signalling promotes therapeutic resistance in ESR1 mutant breast cancerDerek Dustin, Guowei Gu, Amanda R Beyer, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cell Cycle (Georgetown, Tex.)|May 15, 2009
Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signalingJean-Paul De La O, L Charles Murtaugh
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2015
Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived XenograftsMagdalena Bieniasz, Parvathi Radhakrishnan, Najme Faham, et al.
Disease Models & Mechanisms|January 24, 2012
β-catenin is selectively required for the expansion and regeneration of mature pancreatic acinar cells in miceMatthew D Keefe, Hui Wang, Jean-Paul De La O, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 26, 2008
Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasiaJean-Paul De La O, Lyska L Emerson, Jessica L Goodman, et al.
The Oncologist|June 17, 2024
Associations with other cancer-related biomarkers might contribute to poor outcomes in RAS-altered, younger patients with colorectal cancerMadappa N Kundranda, Ariane C Kemkes, Mark C Evans, et al.
Breast Cancer Research : BCR|January 20, 2026
Characterization of ESR1 alterations in patients with breast and gynecologic cancersGargi D Basu, Paige E Innis, Angela K Deem, et al.
Oncotarget|July 25, 2025
Comprehensive genomic profiling of over 10,000 advanced solid tumorsJean-Paul De La O, Jess R Hoag, Angela K Deem, et al.
Journal of Medical Economics|March 31, 2026
Costs and benefits of whole-exome, whole-transcriptome sequencing versus 50-gene panels for genomic profiling in solid tumorsJesse D Ortendahl, Gebra Cuyun Carter, Eliza M Zantema, et al.
Elife|July 8, 2015
The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinomaNathan M Krah, Jean-Paul De La O, Galvin H Swift, et al.
British Journal of Cancer|December 1, 2020
RON signalling promotes therapeutic resistance in ESR1 mutant breast cancerDerek Dustin, Guowei Gu, Amanda R Beyer, et al.
Pageof 1